Drug intelligence / Profile preview

SHR-2005 + SHR-1501 + adebrelimab + bacillus Calmette–Guérin

Development stage: Unknown
Lead developer: Hengrui Therapeutics
Modality: Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

SHR-2005 + SHR-1501 + adebrelimab + bacillus Calmette–Guérin is an investigational combination immunotherapy regimen being developed by Jiangsu Hengrui Medicine for the treatment of bladder cancer. The regimen combines multiple mechanisms of immune activation: SHR-2005 is an FcγR-dependent CD40 agonistic monoclonal antibody that activates antigen-presenting cells; SHR-1501 is an interleukin-15 (IL-15) fusion protein (IL-15RαFc superagonist) designed to stimulate T cell and NK cell proliferation; adebrelimab is a humanized monoclonal antibody targeting programmed death-ligand 1 (PD-L1) to block immune checkpoint inhibition; and bacillus Calmette–Guérin (BCG) is a live attenuated bacterial immunotherapy that induces a localized inflammatory and immune response in the bladder. This combination is designed to synergistically enhance both innate and adaptive antitumor immune responses.

Other names: SHR-2005 + SHR-1501 + adebrelimab + BCGSHR-2005 + SHR-1501 + adebrelimab + bacillus Calmette-GuérinSHR-2005 + SHR-1501 + adebrelimab + bacillus Calmette–Guérin

Targets

CD274 (Programmed cell death protein 1 ligand 1)CD40 (Cluster of differentiation 40 receptor)CD80 (T-lymphocyte activation antigen CD80)IL15RA (Interleukin-15 receptor subunit alpha)IL2RB (IL-2 receptor beta chain)NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)PDCD1 (Programmed cell death protein 1 receptor)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)TLR9 (Toll-like receptor 9)IL2RG (Interleukin-2 receptor gamma subunit)

Beyond the preview

Go deeper on SHR-2005 + SHR-1501 + adebrelimab + bacillus Calmette–Guérin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-2005 + SHR-1501 + adebrelimab + bacillus Calmette–Guérin.